Get the Stockscreener App
4.58
4.57%
0.20
Vir Biotechnology Inc stock is traded at $4.58, with a volume of 1.19M.
It is up +4.57% in the last 24 hours and down -20.07% over the past month.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$4.38
Open:
$4.39
24h Volume:
1.19M
Relative Volume:
1.00
Market Cap:
$636.24M
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.1684
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
+1.33%
1M Performance:
-20.07%
6M Performance:
-52.14%
1Y Performance:
-44.95%
1-Day Range:
$4.39
$4.66
1-Week Range:
$4.25
$4.66
52-Week Range:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
4.58 | 622.35M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Price Clustering Detected in Vir Biotechnology Inc. StockQuarterly Portfolio Summary & Real-Time Buy Signal Notifications - thegnnews.com
Published on: 2025-08-21 00:08:39 - kangso.co.kr
Sentiment Turns Positive on Vir Biotechnology Inc. — Reversal AheadJuly 2025 Price Swings & AI Optimized Trade Strategies - newsyoung.net
Sector Rotation Brings Vir Biotechnology Inc. Into FocusPortfolio Risk Summary & Weekly High Conviction Trade Ideas - kangso.co.kr
Can Vir Biotechnology Inc. recover in the next quarterMarket Movers & Free Real-Time Volume Trigger Notifications - Newser
Vir Biotechnology Inc. stock outlook for YEAR2025 Investor Takeaways & High Accuracy Swing Entry Alerts - Newser
Vir Biotechnology Inc.’s volatility index tracking explained2025 Market Outlook & Long-Term Safe Return Strategies - Newser
How to integrate Vir Biotechnology Inc. into portfolio analysis tools2025 EndofYear Setup & Verified Momentum Stock Alerts - Newser
Predicting Vir Biotechnology Inc. trend using moving averagesJuly 2025 Sentiment & Daily Volume Surge Trade Alerts - Newser
What to expect from Vir Biotechnology Inc. in the next 30 daysMarket Activity Summary & AI Driven Stock Price Forecasts - Newser
Vir Biotechnology Inc. Volume Confirms Breakout — Analysts Bullish2025 Retail Activity & Free Safe Entry Trade Signal Reports - 선데이타임즈
How to track smart money flows in Vir Biotechnology Inc.2025 Market Trends & Low Drawdown Investment Ideas - Newser
Will a bounce in Vir Biotechnology Inc. offer an exitWall Street Watch & Low Drawdown Investment Ideas - Newser
Will earnings trigger a reversal in Vir Biotechnology Inc.July 2025 Snapshot & Safe Capital Investment Plans - Newser
Technical Models Detect Momentum Build in Vir Biotechnology Inc.July 2025 WrapUp & Long Hold Capital Preservation Tips - 선데이타임즈
Why Vir Biotechnology Inc. stock attracts strong analyst attentionGold Moves & Detailed Earnings Play Alerts - Newser
VIR Biotechnology’s SWOT analysis: stock outlook amid clinical trials and cash reserves - Investing.com
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? - MSN
When is the best time to buy Vir Biotechnology Inc. stockReal-Time Entry Signals for Top Stocks - Newser
What is Vir Biotechnology Inc. s revenue forecastMassive Potential Swing Trades - kangso.co.kr
Vir Biotechnology’s Q2 2025: Unraveling Contradictions in ECLIPSE Trials, HDV Prevalence, and T-Cell Strategies - AInvest
Vir Biotechnology’s Earnings Call Highlights Progress and Challenges - TipRanks
Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
Raymond James Sticks to Its Buy Rating for Vir Biotechnology (VIR) - The Globe and Mail
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $12 to $31 - 富途牛牛
Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2025 Earnings Call Transcript - Insider Monkey
Vir Biotechnology (NASDAQ:VIR) Trading Down 11.1% After Earnings Miss - Defense World
Vir Biotechnology (VIR.O) Plunges 14.5%: What’s Driving the Intraday Swoon? - AInvest
Vir Biotechnology's 12.4% Intraday Drop: A Technical and Order-Flow Deep Dive - AInvest
Earnings call transcript: Vir Biotech Q2 2025 results fall short, stock dips - Investing.com
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta - BioSpace
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results - BioSpace
Vir Biotechnology outlines global patient recruitment and cash runway through mid-2027 amid hepatitis delta pipeline momentum - MSN
Vir Biotechnology 2025 Q2 Earnings Losses Narrow 19.8% as Net Income Declines - AInvest
Vir (VIR) Q2 Revenue Drops 61% - The Motley Fool
Vir Biotechnology Reports Q2 2025 Financial Results - TipRanks
Vir Biotechnology's Q2 2025 Performance and Future Outlook: A Contrarian's Playbook for a Biotech Underdog - AInvest
Vir Biotechnology: A High-Conviction Play in Hepatitis Delta and Next-Gen Oncology Innovation - AInvest
Transcript : Vir Biotechnology, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Vir Biotechnology Q2 Earnings Fall Short of Estimates, Revenue Lags Behind - AInvest
Vir Biotechnology Q2 2025 Earnings Call Transcript - MarketBeat
Vir Biotechnology, Inc. SEC 10-Q Report - TradingView
Earnings Flash: (VIR) Vir Biotechnology Q2 Loss $0.80 Vs. FactSet Est. $0.72 Loss - MarketScreener
Vir Biotechnology Q2 revenue misses expectations, net loss narrows - MarketScreener
Vir Biotechnology reports Q2 EPS (80c), consensus (72c) - TipRanks
Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 10c, provides guidance - StreetInsider
Vir Biotechnology enrolls first participant in ECLIPSE 3 trial - TipRanks
Vir Biotechnology successfully initiates all trials in Eclipse registrational program - MarketScreener
Vir Biotechnology completes initiation of hepatitis delta program By Investing.com - Investing.com Nigeria
Vir Biotechnology enrolls first patient in ECLIPSE 3 hepatitis delta trial - StreetInsider
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vir Biotechnology Inc Stock (VIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Eisner Mark | EVP and Chief Medical Officer |
Jul 15 '25 |
Sale |
5.47 |
6,796 |
37,162 |
108,204 |
| Eisner Mark | EVP and Chief Medical Officer |
Jul 17 '25 |
Sale |
5.47 |
3,586 |
19,629 |
104,618 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):